glp 1 agonist with dpp 4 inhibitor Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes Insight into Structure Activity Relationship

Description

doi: 10.3389/fendo.2019.00492 84 VniantMMLuS-CAtanganLKomorowskiRStanislausSChengYet al

glp 1 agonist with dpp 4 inhibitor Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic -cell impairments in type 2 diabetes Insight into Structure Activity Relationship

How it Works: It stabilizes blood sugar and promotes a steady feeling of fullness throughout the day

10.1038/s41392-024-01931-z [DOI] [PMC free article] [PubMed] [Google Scholar] 16.Oprea AD, Umpierrez GE, Sweitzer B, Hepner DL (2024) Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: applying evidence to clinical practice

Renal function should be monitored in patients with renal impairment or when experiencing severe gastrointestinal adverse effects that could lead to dehydration and acute kidney injury